Abstracts tagged "autoimmune diseases"

Abstract Number: 1432 • ACR Convergence 2024
Diagnostic Performance of Mayor Salivary Gland Ultrasound for Diagnosis of Sjögren’s Syndrome in Routine Clinical Practice
Carmen Raya-Santos¹, José Miguel Senabre², José Antonio Bernal³, Rocío Gallego Campuzano⁴, Lara Pons-Canet², Ana Pons-Bas², Juan Carlos Cortes⁴, Gregorio Santos-Soler⁵ and José Rosas-Gómez de Salazar⁶, ¹Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²Hospital Marina Baixa, Villajoyosa, Spain, ³Hospital Marina Baixa (Villajoyosa), Alicante, Spain, ⁴Hospital Marina Baixa, Villajoyosa, Comunidad Valenciana, Spain, ⁵Hospital Marina Baixa, Villajoyosa, ⁶Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain
Background/Purpose: Major salivary glands ultrasound (SGU) is a promising tool in the diagnosis of Sjögren syndrome (SS) and has demonstrated good sensitivity and specificity in…
Abstract Number: 1621 • ACR Convergence 2024
Analysis of Hospitalizations of Adult Patients with Kawasaki’s Disease: A United States Population Based Study
Ufuoma Mamoh¹, Soziema Salia¹, Joan Morny², Jesse Odion³, Elem Ewuru⁴, Precious Onobraigho⁵, Eugene Omoike⁵, Oyidia Ijioma⁶, Osaruese Ezomo⁷ and Ehizogie Edigin⁸, ¹Medstar Union Memorial Hospital, Baltimore, MD, ²Piedmont Athens Regional Medical Center, Athens, GA, ³Royal Devon University Healthcare NHS Foundation Trust, Barnstaple, United Kingdom, ⁴Acute and Emergency Care United Kingdom Medway Maritime Hospital, Gillingham, ⁵College of Medicine, University of Benin, Benin, Nigeria, ⁶Department of Clinical Psychiatry, University of South Wales, Wales, United Kingdom, ⁷Department of Gastroenterology, Spire Manchester Hospital, Manchester, United Kingdom, ⁸The University of Texas Health Science Center, houston, TX
Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis, typically affecting young children, and is the leading cause of acquired heart disease in children in developed…
Abstract Number: 1753 • ACR Convergence 2024
A Phase 1, Multicenter, Open-Label Study to Establish the Preliminary Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process, for Severe, Refractory Autoimmune Diseases
Georg Schett¹, Emily Littlejohn², Neil Kramer³, Amit Saxena⁴, Philip Mease⁵, Margrit Wiesendanger⁶, Fabian Müller⁷, Ran Reshef⁸, Paolo Caimi⁹, Mohamad Cherry¹⁰, Jingmei Hsu⁴, Krish Patel¹¹, Jacques Azzi⁶, Susana Falcon¹², Thomas Ly¹³, Ken Ogasawara¹², Sharmila Das¹², Jerill Thorpe¹⁴, Michael Maldonado¹², Giuseppina Stifano¹², Ashley Koegel¹² and Anca Askanase¹⁵, ¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ²Cleveland Clinic, Cleveland, OH, ³Atlantic Medical Group, Atlantic Health System, Morristown, NJ, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁸Columbia University Irving Medical Center, New York, NY, ⁹Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, ¹⁰Atlantic Health System, Morristown, NJ, ¹¹Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, WA, ¹²Bristol Myers Squibb, Princeton, NJ, ¹³Bristol Myers Squibb, San Diego, CA, ¹⁴Bristol Myers Squibb, Seattle, WA, ¹⁵Columbia University Medical Center, New York, NY
Background/Purpose: CD19 is an appealing therapeutic target due to its ubiquitous expression on B cells and plasmablasts, which play a key role in the pathogenesis…
Abstract Number: 1841 • ACR Convergence 2024
Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases
Kristen Zhang, Joanne Li, Duy Nguyen, Nguyen Tan, Hsin-Yuan Cheng, David Huang, Suhasni Gopalakrishnan, Zachary Roberts, Cesar Sommer and Elvin Lauron, Allogene Therapeutics, South San Francisco, CA
Background/Purpose: Autologous CD19 chimeric antigen receptor (CAR) T cell therapies have recently shown to be well tolerated and highly effective in patients with autoimmune diseases…
Abstract Number: 1940 • ACR Convergence 2024
Timely Initiation of Steroid Sparing Therapy in Uveitis Patients – a Quality Improvement Initiative
Bibi Ayesha¹, Claudia Castiblanco², Clement Tagoe³, Sarah Baron² and Sharon Rikin², ¹Montefiore Medical Center, Metuchen, NJ, ²Montefiore Medical Center, Bronx, NY, ³Montefiore Medical Center, New York
Background/Purpose: Uveitis is the inflammation of the eye, which is third leading cause of preventable blindness in the United States. Corticosteroids are the first line…
Abstract Number: 2078 • ACR Convergence 2024
Increased RAGE Expression in Myositis
Madison King¹, Rita Spathis², Elizabeth Bagley¹ and Melissa Morales³, ¹Binghamton University, Johnson City, NY, ²Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, NY, ³SUNY Binghamton, Johnson City, NY
Background/Purpose: Myositis is a broad term for a group of rare autoimmune diseases that cause persistent muscle inflammation, weakness, and fatigue. Currently, first-line treatment for…
Abstract Number: 2391 • ACR Convergence 2024
Identification of Patients with ANA Negative and Double Stranded DNA Positive: What Is the Significance in Daily Rheumatology Practise
Güllü Sandal Uzun¹, Emily Apsley² and David Isenberg², ¹University College London, London, England, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: The anti-nuclear antibody (ANA test) is a sensitive screening tool used when assessing patients with possible autoimmune rheumatic diseases (ARD). Homogeneous staining positivity is…
Abstract Number: 2531 • ACR Convergence 2024
CRISPR Deletion Screen in Fibroblasts Identifies Novel Regulators of Inflammation
Alisa Mueller¹, Suppawat Kongthong², Angela Zou³, Gerald Watts⁴, Cassandra Murphy², Hung Nguyen², Jacqueline Perrigoue⁵, Mathew Chamberlain⁵, Kevin Wei⁶, Soumya Raychaudhuri² and Michael Brenner⁷, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴Harvard Medical School, Brookline, MA, ⁵Johnson & Johnson, Spring House, PA, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts adopt an inflammatory phenotype that catalyzes pathogenic synovial hyperplasia and ultimately bone and cartilage destruction. However, identifying therapeutic…
Abstract Number: 2662 • ACR Convergence 2024
In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases
Laurie Beitz¹, Maura Parker¹, Justin Ulrich-Lewis¹, Kristen Mittelsteadt¹, Rebecca Gottschalk¹, Chris Nicolai¹, Jim Qin¹, Andrew Scharenberg¹, Ryan Larson¹, Byoung Ryu¹, Eric Cavanaugh², Weiliang Tang¹, Seungjin Shin¹, Kelsey Lynch¹ and Hans-Peter Kiem², ¹Umoja Biopharma, Seattle, WA, ²Fred Hutch Cancer Research Center, Seattle, WA
Background/Purpose: CAR T cell therapy promises to revolutionize the treatment of hematologic malignancies, and more recently has generated early data that it may afford long…
Abstract Number: 0006 • ACR Convergence 2024
NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
Mark Noviski¹, Jun Ma¹, Nivetha Brathaban¹, Aishwarya Kumar¹, Dhwani Haria¹, Jenny McKinnell¹, Robert Cass¹, Frederick Cohen¹, Davorka Messmer², Gwenn Hansen¹ and Ryan Rountree¹, ¹Nurix Therapeutics, San Francisco, CA, ²Nurix Therapeutics, San Diego, CA
Background/Purpose: Bruton’s tyrosine kinase (BTK) mediates signaling downstream of the B cell receptor (BCR), toll-like receptors (TLRs), and Fc receptors (FcRs). This makes BTK an…
Abstract Number: 0089 • ACR Convergence 2024
Single-Cell RNA Sequencing Outlines the Mechanisms of Vgll3-Driven Myofibroblasts Differentiation in Promoting Fibrosis in Cutaneous Lupus
Mehrnaz Gharaee-Kermani, Allison Billi, Poulami Dey, Jacob Martens, Marisa Hildebrandt, J. Michelle Kahlenberg and Johann Gudjonsson, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin fibrosis is characterized by collagen deposition, fibro/myofibroblast accumulation, and extracellular matrix remodeling. Some subtypes of cutaneous lupus erythematosus (CLE), particularly discoid lupus erythematosus…
Abstract Number: 0248 • ACR Convergence 2024
Recombinant Herpes Zoster Vaccine in a Large Cohort of Autoimmune Rheumatic Diseases Patients: An Interim Analysis of a Prospective Randomized Phase 4 Study
Nadia Aikawa¹, Ana Cristina Medeiros-Ribeiro², Sandra Pasoto³, Leonard Kupa³, Luciana Seguro⁴, ANA PAULA ASSAD³, Eduardo Borba³, Carla Goncalves Schahin Saad⁴, Emily Figueiredo Neves Yuki³, Danieli Andrade⁵, Andrea Shimabuco⁴, Karina Bonfiglioli³, Diogo Domiciano³, Julio Moraes³, Samuel Shinjo⁴, Percival Sampaio-Barros⁴, Henrique Giardini³, Joao de Oliveira³, Isabele Antonelli³, Renata Pinheiro³, Thais Bonini³, Marta Lopes⁶, Clovis Silva⁷ and Eloisa Bonfa³, ¹Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵University of São Paulo, São Paulo, SP, Brazil, ⁶Infectious Disease Department, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ⁷Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are at high risk of herpes zoster (HZ) due to their condition and treatment. The new recombinant vaccine…
Abstract Number: 0312 • ACR Convergence 2024
The Use of Electromyography as a Screening Tool in Sarcoidosis-associated Neuropathy
Kristen Caldwell¹, Sindhuja Koppu¹, Huzaefah Syed², Aamer Syed¹, Jordana Kron¹, Thomas Iden¹ and Kelly Gwathmey¹, ¹Virginia Commonwealth University, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA
Background/Purpose: Small fiber neuropathy (SFN) is the most common peripheral nervous system manifestation of sarcoidosis. Diagnosis of SFN includes clinical evaluation, occasionally skin biopsy to…
Abstract Number: 0476 • ACR Convergence 2024
Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study of 72 Patients
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesús Alejandro Valero Jaimes³, Marta Pastor-Mena⁴, Rafael Benito Melero-Gonzalez⁵, María Martín López⁶, Santos Castañeda⁷, Jesús Loarce⁸, César Antonio Egües Dubuc⁹, Natalia Mena Vázquez¹⁰, Carmen Carrasco-Cubero¹¹, Carolina Perez-Garcia¹², Juan M Blanco Madrigal¹³, Nuria Vegas Revenga¹⁴, Lorena Pérez Albadalejo¹⁵, Rafaela Ortega-Castro¹⁶, Desiree Palma¹⁷, Ana Fernández-Ortiz¹⁸, Maria López Lasanta¹⁹, Marta Garijo Bufort²⁰, Ivette Casafont-Sole²¹, Andrea García-Valle²², Maria Paz Martinez-Vidal²³, Bryan Josué Flores Robles²⁴, EVELIN CERVANTES PEREZ²⁵, Ignacio Brana Abascal²⁶, Sara María Rojas Herrera²⁷, Juan Camilo Sarmiento-Monroy²⁸, Virginia Ruiz-Esquide²⁹, JOSE RAMON LAMUA RIAZUELO³⁰, Uxue Astigarraga-Urquia³¹, Diego Ferrer³² and Ricardo Blanco-Alonso³³, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Zumarraga Hospital, Zumarraga, Spain, ⁴Hospital de Jeréz de la Frontera, Cadiz, Spain, ⁵CHU Ourense, O Carballino, Spain, ⁶General University Hospital of Ciudad Real, Ciudad de México, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁹Hospital Universitario de Donostia, Donostia, Pais Vasco, Spain, ¹⁰IBIMA, Málaga, Andalucia, Spain, ¹¹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹²Hospital del Mar, Barcelona, Spain, ¹³BASURTO UNIVERSITY HOSPITAL, Bilbao, Spain, ¹⁴Hospital Galdakao- Usansolo, Galdakao, Spain, ¹⁵Hospital Universitario de Jaén, Jaén, Spain, ¹⁶Hospital Reina Sofía, Cordoba, Andalucia, Spain, ¹⁷Hospital Rafael Méndez, Lorca, Murcia, Spain, ¹⁸Hospital Universitario de Badajoz, Badajoz, Spain, ¹⁹Hospital Vall d�Hebron, Barcelona, Spain, ²⁰Hospital de Sagunto, Valencia, Spain, ²¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²²Hospital General Río Carrión, Palencia, Spain, ²³Hospital San Juan de Alicante, Alicante, Spain, ²⁴Hospital San Pedro, Logroño, Spain, ²⁵Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain, ²⁶Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ²⁷Hospital de Mérida, Badajoz, Spain, ²⁸Hospital Clínic Barcelona, Barcelona, Spain, ²⁹Hospital Clinic de Barcelona, Barcelona, Spain, ³⁰Hospital Universitario del Henares, Madrid, Spain, ³¹Hospital Universitario de Navarra, Pamplona, Spain, ³²Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA) that determines a worse prognosis, leading the cause of mortality in RA…
Abstract Number: 0705 • ACR Convergence 2024
Identification of Risk Factors for Incident Cardiomyopathy in Patients with Systemic Sclerosis
Ji Soo Kim¹, Rachel Wallwork¹, Carrie Richardson², Adrianne Woods³, Monica Mukherjee⁴, Steven Hsu⁴, Julie Paik¹, Christopher Mecoli¹, Laura Hummers⁵, Fredrick Wigley⁶, Scott Zeger¹ and Ami Shah⁷, ¹Johns Hopkins University, Baltimore, MD, ²Northwestern University, Chicago, ³Johns Hopkins University Division of Rheumatology, Baltimore, MD, ⁴Johns Hopkins University Division of Cardiology, Baltimore, MD, ⁵Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁶Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ⁷Division of Rheumatology, Johns Hopkins University, Ellicott City, MD
Background/Purpose: Cardiac involvement in systemic sclerosis (SSc) is one of the leading causes of scleroderma-associated death. There are limited data examining risk factors for incident…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].